Sodium-lithium countertransport activity in healthy, dyslipidemic, and hypertensive individuals

Area of Science:

• Cardiovascular Physiology
• Biochemistry
• Clinical Medicine

Background:

• Red blood cell sodium-lithium countertransport is a marker for essential hypertension.
• Dyslipidemia is a known risk factor for cardiovascular disease.
• The interplay between dyslipidemia, hypertension, and cellular ion transport requires further investigation.

Purpose of the Study:

• To investigate the influence of dyslipidemia on red blood cell sodium-lithium countertransport activity.
• To compare this activity in healthy and hypertensive individuals with and without dyslipidemia.
• To determine whether dyslipidemia affects this activity independently of hypertension.

Main Methods:

• A study involving 128 Caucasian individuals aged 20-60 years.
• Participants were categorized into four groups: dyslipidemic/hypertensive, dyslipidemic/normotensive, normolipidemic/hypertensive, and normolipidemic/normotensive (controls).
• Sodium-lithium countertransport activity was measured using the Canessa et al method.

Main Results:

• Sodium-lithium countertransport activity was significantly higher in all patient groups compared to controls (P < .001).
• Activity levels were similar across the three patient groups (dyslipidemic/hypertensive, dyslipidemic/normotensive, normolipidemic/hypertensive).
• Activity showed significant positive associations with triglyceride levels (P < .001), body mass index (P < .001), total cholesterol (P = .001), systolic blood pressure (P = .001), and diastolic blood pressure (P = .001).
• Multivariate regression identified triglycerides as the primary contributor to countertransport variation (R(2) = 0.273).

Conclusions:

• Dyslipidemia significantly impacts red blood cell sodium-lithium countertransport activity.
• This effect appears to be independent of essential hypertension.
• Dyslipidemia exerts a greater influence on sodium-lithium countertransport activity than hypertension itself.